4th Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for AMGEN USA INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Medicare Part D; Medicare Part B; S. 1416 - Affordable Prescriptions for Patients Act of 2019; H.R.3 - Lower Drug Costs Now Act of 2019; H.R. 2693 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019

LobbyistCovered position, as disclosed
NADEAM ELSHAMI —
EMILY FELDER —
ELIZABETH ANNE MAIER —
ALFRED MOTTUR —
JEROME MURRAY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1416 (116th), H.R. 2693 (116th), H.R. 3 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.